

CLINICIAN GUIDE

CORUS<sup>®</sup> CAD

WOMEN AND  
OBSTRUCTIVE CAD

Assessing women for  
obstructive CAD can be difficult.  
Now, a simple blood test can  
help you exclude this diagnosis.



The only sex-specific test to evaluate the likelihood  
of obstructive CAD right in your office

## A simple blood test can help you rule out the need for further evaluation of obstructive CAD.\*

Women with symptoms suggestive of obstructive coronary artery disease (CAD) are often more difficult to diagnose than men, due to nonspecific, atypical symptoms as well as lower performance of traditional noninvasive testing in women.<sup>†, 1-4</sup> But now, the Corus<sup>®</sup> CAD test, in conjunction with your clinical assessment, can help you rule out the need for further evaluation for obstructive CAD. Performed through a quick, routine blood draw, results are available within a few days.

### What makes the test useful?

The test has been clinically validated in the PREDICT and COMPASS studies, two prospective, multicenter U.S. clinical studies evaluating patients referred for invasive angiography and myocardial perfusion imaging (MPI), respectively.<sup>5,6</sup>

**In the COMPASS study, Corus CAD demonstrated a negative predictive value of 96%<sup>‡</sup>, thus improving the classification of patient disease status.**

Furthermore, in the COMPASS study, Corus CAD outperformed MPI in excluding obstructive CAD as the cause of patients' symptoms.<sup>6</sup>

\*Obstructive coronary artery disease (CAD) is defined as at least one atherosclerotic plaque causing  $\geq 50\%$  luminal diameter stenosis in a major coronary artery ( $\geq 1.5\text{mm}$  lumen diameter) as determined by invasive quantitative coronary angiography (QCA) or core-lab computerized tomography angiography (CTA) ( $\geq 2.0\text{mm}$  lumen diameter).

<sup>†</sup>Sensitivity of MPI in women demonstrated to be 78% vs. 85% in men. Sensitivity of EKG in women demonstrated to be 61% vs. 68% in men.

<sup>‡</sup>The COMPASS study found that the Corus CAD algorithm has an NPV of 96% at the pre-specified threshold of 15 in the overall population of men and women referred to MPI.



## How does Corus CAD work?

The Corus CAD algorithm integrates age, sex, and gene expression to calculate a score. Combining the Corus CAD score with other patient information provides you with a more complete picture of your patient's CAD status through its clinical validity in identifying patients unlikely to have obstructive CAD.

## What is gene expression?

Whereas genetic testing may inform on lifetime disease risk, a gene expression test provides a current-state assessment. Gene expression levels change depending on a person's disease status resulting from genetic and environmental factors.

## Patient selection for the Corus CAD test.

Corus CAD is intended for patients who present with stable symptoms suggestive of obstructive CAD, such as:

- Chest discomfort, pain, or tightness
- Heartburn
- Shortness of breath
- Back pain

The Corus CAD test is NOT intended for patients who have a history of obstructive CAD, have had a prior myocardial infarction or revascularization procedure, are diabetic, or are currently taking steroids, immunosuppressive agents, or chemotherapeutic agents.

For a complete description of the intended use population, visit [www.cardiodx.com/corus-cad-intended-use](http://www.cardiodx.com/corus-cad-intended-use).

## Get to the root cause.

By quickly determining the likelihood of obstructive CAD as a diagnosis, you may be able to keep your patient from having to undergo additional—often unnecessary and invasive—advanced cardiac testing and minimize her exposure to radiation from medical imaging.



## To help you incorporate Corus<sup>®</sup> CAD into your practice, CardioDx<sup>®</sup> offers:

- Clinician product support and training
- Specialized consultations with CardioDx Medical Affairs to assist in patient selection and test result interpretation
- Easy, 24-hour access to your patients' reports and customized charts and tables through our secure, web-based Clinician Access Portal
- Phlebotomy support and solutions

To order the Corus CAD test, contact your local sales representative, or contact CardioDx Customer Service at 1.866.941.4996 or [service@cardiodx.com](mailto:service@cardiodx.com).



**CARDIODX**

### CardioDx

600 Saginaw Drive  
Redwood City, CA 94063  
P 866.941.4996  
[www.cardiodx.com](http://www.cardiodx.com)

### Customer Service

[service@cardiodx.com](mailto:service@cardiodx.com)  
P 866.941.4996

### Medical Affairs

[medicalaffairs@cardiodx.com](mailto:medicalaffairs@cardiodx.com)  
P 866.941.4996

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, CardioDx is committed to expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies.

#### REFERENCES:

1. Kwok Y, Kim C, Grady D, et al. Meta-Analysis of Exercise Testing to Detect Coronary Artery Disease in Women. *Am J Cardiol*. 1999;83(5):660-665. 2. Burrell S, MacDonald A. Artifacts and Pitfalls in Myocardial Perfusion Imaging. *J Nucl Med Technol*. 2006;34(4):193-211. 3. Mora S, Redberg RF, Cui Y, et al. Ability of Exercise Testing to Predict Cardiovascular and All-Cause Death in Asymptomatic Women: A 20-Year Follow-up of the Lipid Research Clinics Prevalence Study. *JAMA*. 2003;290(12):1600-1607. 4. Dolor RJ, Patel MR, Melloni C, et al. Noninvasive Technologies for the Diagnosis of Coronary Artery Disease in Women. *Comparative Effectiveness Review No. 58*. AHRQ Publication No. 12-EHC034-EF June 2012. 5. Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients. *Ann Intern Med*. 2010;153:425-434. 6. Thomas GS, Voros S, McPherson JA, et al. A Blood-Based Gene Expression Test for Obstructive Coronary Artery Disease Tested in Symptomatic Nondiabetic Patients Referred for Myocardial Perfusion Imaging: The COMPASS Study. *Circ Cardiovasc Genet*. 2013;6(2):154-162.

LEN-120003 Rev. 4 | 0315 | ©2015 CardioDx, Inc. All rights reserved. CardioDx, the CardioDx logo, Corus, and the Corus logo are registered trademarks of CardioDx, Inc., in the U.S. and other countries.